SANGAMO THERAPEUTICS, INC
SGMOQUS売上高
$40M
百万USD
営業利益
$-121M
百万USD
純利益
$-123M
百万USD
ROE
861.6%
最新FY
EPS
$-0.44
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $26M | $-46M | - |
| FY2021 | Q2 | $28M | $-47M | $-0.33 |
| FY2021 | Q3 | $29M | $-48M | $-0.33 |
| FY2021 | FY | $111M | $-178M | $-1.23 |
| FY2022 | Q1 | $28M | $-44M | $-0.30 |
| FY2022 | Q2 | $29M | - | $-0.29 |
| FY2022 | Q3 | $26M | - | $-0.34 |
| FY2022 | FY | $111M | $-192M | $-1.25 |
| FY2023 | Q1 | $158M | $21M | $0.12 |
| FY2023 | Q2 | $7M | $-115M | $-0.66 |
| FY2023 | Q3 | $9M | $-104M | $-0.59 |
| FY2023 | FY | $176M | $-258M | $-1.48 |
| FY2024 | Q1 | $0M | $-49M | $-0.27 |
| FY2024 | Q2 | $0M | $-36M | $-0.18 |
| FY2024 | Q3 | $49M | $11M | $0.04 |
| FY2024 | FY | $58M | $-98M | $-0.49 |
| FY2025 | Q1 | $6M | $-31M | $-0.14 |
| FY2025 | Q2 | $18M | $-20M | $-0.08 |
| FY2025 | Q3 | $1M | $-35M | $-0.11 |
| FY2025 | FY | $40M | $-123M | $-0.44 |
| FY2026 | Q1 | $1M | $-31M | $-0.08 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $84M | $102M | $118M | $111M | $111M | $176M | $58M | $40M |
| 営業利益 | $-73M | $-56M | $-77M | $-105M | $-130M | $-183M | $-201M | $-274M | $-104M | $-121M |
| 純利益 | $-72M | $-55M | $-68M | $-95M | $-121M | $-178M | $-192M | $-258M | $-98M | $-123M |
| 総資産 | $158M | $287M | $590M | $638M | $939M | $722M | $563M | $165M | $102M | $60M |
| 純資産 | - | - | $367M | $433M | $497M | $375M | $295M | $83M | - | - |
| 自己資本 | $136M | $188M | $367M | $433M | $498M | $375M | - | $83M | $23M | $-14M |
| 営業CF | - | - | $37M | $-144M | $170M | $-233M | $-224M | $-225M | $-67M | $-97M |
| EPS | - | - | - | - | - | $-1.23 | $-1.25 | $-1.48 | $-0.49 | $-0.44 |
| BPS | $1.92 | $2.18 | $3.58 | $3.73 | $3.48 | $2.57 | - | $0.46 | $0.10 | $-0.03 |
| ROE | -52.6% | -29.0% | -18.6% | -22.0% | -24.3% | -47.5% | - | -311.1% | -430.1% | 861.6% |